Similarly, PARP1 has been shown to modulate sensitivity to therapy, and olaparib-based therapy significantly enhanced the sensitivity of pancreatic cancer cells (particularly the p53 mutant cells) and other isogenic cancer cell lines to radiotherapy, by inducing cell cycle arrest in G2, homologous recombination repair inhibition, and persistent DNA damage responses [30]. The gene discussed is TP53; the disease is cancer.